TEM
NASDAQTempus AI Inc.
News25/Ratings12
Price$68.74+22.24 (+47.84%)
2026-05-212026-08-25
News · 26 weeks127-5%
2026-03-012026-08-23
Mix6090d
- Insider23(38%)
- Other18(30%)
- SEC Filings14(23%)
- Earnings3(5%)
- Analyst1(2%)
- Leadership1(2%)
Latest news
25 items- SECSEC Form 144 filed by Tempus AI Inc.144 - Tempus AI, Inc. (0001717115) (Subject)
- INSIDERCEO, Diagnostics Schoenherr Thomas Edward increased direct ownership by 3% to 87,021 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERCEO, Data Fukushima Ryan sold $1,000,020 worth of shares (14,286 units at $70.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- PRTempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGsECG-PH clearance adds pulmonary hypertension to Tempus’ FDA-cleared AI products for atrial fibrillation and low ejection fraction Tempus AI, Inc. (NASDAQ:TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an AI-enabled software device that analyzes standard 12-lead electrocardiograms (ECGs) for signs associated with pulmonary hypertension. Tempus ECG-PH is the third FDA-cleared device in Tempus’ growing cardiovascular portfolio, expanding the company’s suite of next-generation AI products aimed at identifying patients at risk for complex cardiac conditions. PH is characterized by stiffening a
- INSIDERCEO, Diagnostics Schoenherr Thomas Edward sold $929,990 worth of shares (17,314 units at $53.71) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 89,715 units (SEC Form 4) (for withholding tax)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERCEO and Chairman Lefkofsky Eric P sold $6,577,840 worth of shares (132,591 units at $49.61), decreasing direct ownership by 6% to 2,098,130 units (SEC Form 4) (for tax liability)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERCEO, Data Fukushima Ryan sold $2,038,723 worth of shares (41,095 units at $49.61), decreasing direct ownership by 7% to 562,463 units (SEC Form 4) (withholding obligation)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERChief Financial Officer Rogers James William sold $2,696,444 worth of shares (48,842 units at $55.21) as part of a pre-agreed trading plan, decreasing direct ownership by 32% to 106,024 units (SEC Form 4) (tax liability)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDEREVP, Chief Legal Officer Polovin Andrew sold $1,542,674 worth of shares (30,075 units at $51.29) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 138,140 units (SEC Form 4) to satisfy tax liability4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERChief Accounting Officer Bartolucci Ryan M sold $306,342 worth of shares (6,175 units at $49.61), decreasing direct ownership by 8% to 67,866 units (SEC Form 4) (tax liability)4 - Tempus AI, Inc. (0001717115) (Issuer)
- SECSEC Form 144 filed by Tempus AI Inc.144 - Tempus AI, Inc. (0001717115) (Subject)
- INSIDERDirector West Nadja sold $161,700 worth of shares (3,000 units at $53.90) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 34,981 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERCEO, Data Fukushima Ryan gifted 62,239 shares (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERCEO, Data Fukushima Ryan sold $1,000,800 worth of shares (20,000 units at $50.04) as part of a pre-agreed trading plan (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- PRAI Found an Influenza Target That Survives Viral MutationAUSTIN, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and two that do not are treated as unrelated. That assumption is convenient and it is frequently wrong, because biology routinely arrives at the same functional outcome through structures that share no obvious sequence similarity. MindWalk Holdings Corp. (NASDAQ:HYFT) has built its entire technology stack around that gap, and in late July it put the result on a stage in front of the AI infrastructure industry. Three Layers, One Idea MindWalk describes itself as a Bio-Native AI c
- PRCellCarta Adds Tempus to CDx Commercialization Lab NetworkTempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta's CDx Accelerator Model.MONTREAL, Aug. 6, 2026 /PRNewswire/ -- CellCarta, a global CRO laboratory supporting the biopharmaceutical industry, today announced a strategic collaboration with Tempus AI, Inc. (NASDAQ:TEM). Under the agreement, CellCarta will include Tempus in its CDx Commercialization Lab Network as the network's second commercial laboratory partner, strengthening oncology-focused companion diagnostics offerings to biopharma sponsors. Within the CellCarta network, the collaboration gives biopharma sponsors
- INSIDERDirector Epstein David R sold $16,058 worth of shares (370 units at $43.40) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 31,094 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERCEO, Data Fukushima Ryan sold $1,100,076 worth of shares (23,818 units at $46.19) as part of a pre-agreed trading plan (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- PRTempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic ApplicationsTempus' multimodal foundation model offers diagnostic-grade precision for cancer detection and unlocks broader applications predicting biomarker status and patient prognosis Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced study results demonstrating that PRISM2, a multimodal slide-level pathology foundation model developed in collaboration with researchers from Microsoft, can perform clinically important diagnostic tasks using simple prompts and can be leveraged for a variety of downstream applications. The results were published in Nature Medicine. PRISM2 outperformed or matched existing slide
- SECSEC Form 144 filed by Tempus AI Inc.144 - Tempus AI, Inc. (0001717115) (Subject)
- INSIDEREVP, Chief Legal Officer Polovin Andrew was granted 40,000 shares, increasing direct ownership by 31% to 168,215 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERChief Financial Officer Rogers James William was granted 40,000 shares, increasing direct ownership by 35% to 154,866 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERCEO and Chairman Lefkofsky Eric P sold $10,514,914 worth of shares (250,000 units at $42.06) as part of a pre-agreed trading plan (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- SECSEC Form 10-Q filed by Tempus AI Inc.10-Q - Tempus AI, Inc. (0001717115) (Filer)
- SECTempus AI Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Tempus AI, Inc. (0001717115) (Filer)
TEM FAQ
6 questionsWhere does TEM stock trade?
Tempus AI Inc. (TEM) is listed on NASDAQ.What sector and industry is TEM in?
Tempus AI Inc. operates in the Technology sector, Computer Software: Programming Data Processing industry.When did Tempus AI Inc. go public?
Tempus AI Inc. (TEM) completed its IPO in 2024.What are analysts saying about TEM?
Tempus AI Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-06-02. Recent price targets cluster around $3500.00.What companies are similar to TEM?
Notable peers in the same industry include GOOGL (Alphabet Inc.), GOOG (Alphabet Inc.), META (Meta Platforms Inc.), APP (Applovin Corporation), NBIS (Nebius Group N.V.). Compare TEM side-by-side with any of them on Quantisnow.How can I track TEM on Quantisnow?
Quantisnow aggregates Tempus AI Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TEM to receive live email and push alerts on every new disclosure.